Newcastle University Launches Advanced Cancer Testing Facility

A new cancer testing facility is set to open at Newcastle University in mid-2026, marking a significant advancement in the fight against cancer. This innovative hub will be operated by Curium International, a leading firm in the production of diagnostic materials. The centre will focus on creating a “diagnostic radiotracer” essential for PET scans, which are critical for diagnosing and monitoring various illnesses, including cancer and heart disease.

The facility will be located in the Bedson Building on Newcastle University’s campus, in close proximity to the Royal Victoria Infirmary. University officials have expressed enthusiasm about the new partnership, highlighting its potential to enhance healthcare in the region. Professor Quentin Anstee, Pro-Vice-Chancellor for the Faculty of Medical Sciences at Newcastle University, stated, “This partnership with Curium brings further leading-edge care, research, and innovation to the region.”

The collaboration aims to accelerate the development of faster diagnostic and treatment options for patients. Professor Anstee emphasized the importance of translating research into practical healthcare solutions, noting that this initiative aligns with the university’s mission to improve the quality and longevity of life for individuals.

Innovations in nuclear technology are at the forefront of this effort, with expectations that the new facility will significantly enhance access to advanced diagnostic tools. It is projected that the hub will support all PET and CT scanners in the North East, thus improving brain imaging and cancer diagnosis for patients in the area.

Dr. Meera Vijayaraghavan, who spearheaded the commercial arrangements for the university, remarked on the growing connections between academic research and the med-tech industry. “From drug discovery through diagnostic medicine to treatment plans, we’re building more links with commercial partners,” she said. “This new arrangement with Curium complements the work in our Centre for In Vivo Imaging and adds vital capabilities to the med-tech cluster in North East England.”

Curium’s General Manager for the UK and Ireland, Ruairi O’Donnell, highlighted the company’s commitment to expanding access to essential diagnostic tests. He noted that nuclear technology plays a crucial role in disease diagnostics and has the potential to transform cancer treatment for up to 80% of cancers within the next 10-15 years. O’Donnell stated, “Our investment in Newcastle, alongside other parts of the country, is a clear commitment from Curium that we are determined to increase access further.”

The establishment of this cutting-edge facility represents a significant milestone in cancer research and treatment, with the potential to benefit countless patients in the region and beyond. As the project progresses, both Newcastle University and Curium International are poised to lead the way in innovative cancer care and diagnostics.